Differences in clinicopatholgic characteristics and risk of mortality between the triple positive and ER+/PR+/HER2-breast cancer subtypes

Parise Carol A.; Caggiano Vincent

首页> 外文期刊>Cancer causes and control: CCC >Differences in clinicopatholgic characteristics and risk of mortality between the triple positive and ER+/PR+/HER2-breast cancer subtypes

【24h】

Differences in clinicopatholgic characteristics and risk of mortality between the triple positive and ER+/PR+/HER2-breast cancer subtypes

机译：临床疗法特征的差异以及三重阳性和ER + / PR + / HER2-乳腺癌亚型之间的死亡风险

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Purpose This study compared the demographic and clinicopathologic characteristics and risk of mortality between the triple positive (TP) and ER+/PR+/HER2- breast cancer subtypes.

机译：目的本研究比较了三重阳性（TP）和ER + / PR + / HER2-乳腺癌亚型之间的人口统计和临床病理特征和死亡风险。

著录项

来源
《Cancer causes and control: CCC》 |2019年第5期|共8页
作者
Parise Carol A.; Caggiano Vincent;
展开▼
作者单位

Sutter Inst Med Res 2801 Capitol Ave Suite 400 Sacramento CA 95816 USA;

Sutter Inst Med Res 2801 Capitol Ave Suite 400 Sacramento CA 95816 USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词
Breast cancer; Luminal B; Triple positive; Mortality; Risk factors; Population-based registry;

机译：乳腺癌;Luminal B;三重阳性;死亡率;危险因素;基于人口的注册表;

相似文献

外文文献
中文文献
专利

1. Differences in clinicopatholgic characteristics and risk of mortality between the triple positive and ER+/PR+/HER2-breast cancer subtypes [J] . Parise Carol A., Caggiano Vincent Cancer causes and control: CCC . 2019,第5期

机译：临床疗法特征的差异以及三重阳性和ER + / PR + / HER2-乳腺癌亚型之间的死亡风险
2. Identification of long non?coding RNA?mediated transcriptional dysregulation triplets reveals global patterns and prognostic biomarkers for ER+/PR+, HER2? and triple negative breast cancer [J] . DuZhengwei, GaoWei, SunJiayi, International journal of molecular medicine . 2019,第3期

机译：鉴定长的非α编码RNA？介导的转录失调三联网揭示了ER + / PR +，HER2的全局模式和预后生物标志物？和三重阴性乳腺癌
3. Impact of chemotherapy relative dose intensity on cause-specific and overall survival for stage I-III breast cancer: ER+/PR+, HER2-vs. triple-negative [J] . Zhang Lu, Yu Qingzhao, Wu Xiao-Cheng, Breast cancer research and treatment. . 2018,第1期

机译：化疗相对剂量强度对阶段I-III乳腺癌的原因特异性和总生存的影响：ER + / PR +，HER2-VS。三负
4. Differences in lung cancer mortality trends from 1986-2011 by radon risk areas in British Columbia, Canada [C] . Sarah B. Henderson, Stephen Rauch, Perry Hystad, Annual conference of the International Society of Exposure Science . 2014

机译：1986-2011年加拿大不列颠哥伦比亚省ra气风险地区肺癌死亡率趋势的差异
5. Preclinical exploration of novel small molecules as anticancer agents in triple-negative and HER2/neu-positive breast cancers. [D] . Weng, Shu-Chuan. 2008

机译：在三阴性和HER2 / neu阳性乳腺癌中作为抗癌药的新型小分子的临床前探索。
6. Passive Smoking Exposure from Partners as a Risk Factor for ER+/PR+ Double Positive Breast Cancer in Never-Smoking Chinese Urban Women: A Hospital-Based Matched Case Control Study [O] . Jian-hua Tong, Zhi Li, Jing Shi, -1

机译：来自伴侣的被动吸烟暴露是中国从不吸烟的城市女性ER + / PR +双阳性乳腺癌的危险因素：一项基于医院的配对病例对照研究
7. Passive smoking exposure from partners as a risk factor for ER+/PR+ double positive breast cancer in never-smoking Chinese urban women: a hospital-based matched case control study. [O] . Jian-hua Tong, Zhi Li, Jing Shi, 2014

机译：合作伙伴的被动吸烟暴露是中国城市女性从不吸烟的ER + / pR +双阳性乳腺癌的危险因素：基于医院的匹配病例对照研究。

Differences in clinicopatholgic characteristics and risk of mortality between the triple positive and ER+/PR+/HER2-breast cancer subtypes

摘要

著录项

相似文献

相关主题

期刊订阅